A new tool in the fight against foodborne infections
Noroviruses account for a large share of foodborne illnesses caused by consumption of contaminated produce. But a team of researchers recently developed a novel method for combating them. They used a combination of cranberry juice and fruit extract to create an edible coating that can be applied to produce. When used in conjunction with gamma irradiation, the coating helps eliminate contamination without affecting the quality of the produce or posing a risk to consumers.
Monique Lacroix, a researcher at Institut National de la Recherche Scientifique, developed the coating, which is sprayed on fresh fruit or vegetables that are subsequently treated with cold pasteurization, such as irradiation. Because the organic acids and polyphenols in the fruit extract help to inhibit viral activity, a much lower dose of gamma rays or x-rays can be used. The reduction in dosage is important because while irradiation destroys noroviruses, it can, at higher dosages, also alter some of the properties of the produce.
“Noroviruses usually require an irradiation dose of three kilograys, but we have shown that the treatment time is reduced by half with this fruit mixture spray, which acts as a natural antimicrobial,” explained Lacroix in a press release.
Having been the first team to test the fruit extract mixture as part of a combined treatment, Lacroix and her colleagues were able to demonstrate the efficacy of their two-step approach, described in the Journal of Applied Microbiology. “Both the juice and extract have the ability to remove noroviruses when used alone, but when combined with cold pasteurization in the same treatment, the fruit concentrations required are significantly lower,” she noted.
The next step for Lacroix and her colleagues is to collaborate with the food industry to test a variety of natural fruit extract and cold pasteurization treatments on a commercial scale.
Biopharma's Future: Made in China
2026-09-07
Trade Alert
Delivering the latest product trends and industry news straight to your inbox.
(We'll never share your email address with a third-party.)
Related News
-
Pfizer's paxlovid reduces the risk of COVID-19 by 26%
-
The battle between Pfizer and Gilead over COVID-19 drugs will continue
-
1200 cases were newly prescribed by Junshi Biologic for mild to moderate disease
-
Twenty-five COVID-19 Vaccines In China Enter Stages Of Clinical Trials
-
Pfizer to Increase Production Capacity of COVID-19 Oral Drugs, Invest 120 Million US Dollars
-
Anke Bio and Afana Collaborate on mRNA Vaccines for Mutant Strains Such as COVID-19 Omicron
-
As Low as $25/session! Pfizer's COVID-19 Oral Drug Paxlovid Generic Drug Price Released
-
Survey On Corona Deaths By Country
-
COVID-19 Drug Remdesivir Approved for Infants And Young Children
-
Roche's Q1 Performance Increases by 10%, And Total Revenue for the Year May Slow Down Due to COVID-19, Biosimilar Competition
Recommend Reading
-
Nestlé Drops Artificial Colors Worldwide by 2026: Food Additives Face a Reformulation Shock
-
Agrochemical Markets at a Crossroads: Winter Stockpiling Begins Amid Cost Pressures and Fragmented Demand
-
Jiangsu Fengshan Biochem Gears Up for Strategic Expansion in Selective Herbicide Intermediates and Active Ingredients
-
Afidopyropen: The Silent Assassin of Sap-Sucking Pests—Promise, Pitfalls, and the Path to Sustainable Deployment
-
Vertex Buys Crinetics for $10 Billion: Rare Disease M&A Is Back
-
China’s Hybio Takes Generic Tirzepatide to FDA: Lilly’s GLP-1 Fortress Gets a Warning Shot
-
Recent Acetic Acid Market Continues to Operate Strongly in China
-
Medicare’s $50 GLP-1 Door Opens: Weight-Loss Drug Demand Just Got Bigger
-
BDO Market Conditions Remain Stale and Await Further Developments
-
Downstream Demand Releases, Formic Acid Prices Steadily Rise